ארצות הברית - אנגלית - NLM (National Library of Medicine)

alembic pharmaceuticals limited - clonazepam (unii: 5pe9fde8gb) (clonazepam - unii:5pe9fde8gb) - seizure disorders: clonazepam orally disintegrating tablet is useful alone or as an adjunct in the treatment of the lennox-gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. in patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam orally disintegrating tablets may be useful. in some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. in some cases, dosage adjustment may reestablish efficacy. panic disorder: clonazepam orally disintegrating tablet is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in dsm-v. panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. the efficacy of clonazepam orally disintegrating tablets was established in two

ארצות הברית - אנגלית - NLM (National Library of Medicine)

alembic pharmaceuticals limited - doxepin hydrochloride (unii: 3u9a0fe9n5) (doxepin - unii:5asj6huz7d) - doxepin hydrochloride capsules are recommended for the treatment of: - psychoneurotic patients with depression and/or anxiety. - depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). - depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). - psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. the target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. clinical experience has shown that doxepin hydrochloride capsule is safe and well tolerated even in the elderly patient. owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsule is not recommended for use in childre

טנזניה - אנגלית - Tanzania Medicinces & Medical Devices Authority

cadila pharmaceuticals limited, india - dicyclomine , paracetamol - tablets - 20+500

טנזניה - אנגלית - Tanzania Medicinces & Medical Devices Authority

sri balaji pharma limited, tanzania - sodium hypochrolite - solution - 3.5

טנזניה - אנגלית - Tanzania Medicinces & Medical Devices Authority

lincoln pharmaceuticals limited, india - dicyclomine , paracetamol - tablets - 20/500

הממלכה המאוחדת - אנגלית - myHealthbox

bayer ag -

ארצות הברית - אנגלית - NLM (National Library of Medicine)

flex beauty labs - ethyl alcohol 62%........ antiseptic - antiseptic decresases bacteria on skin do not use if you are allegic to any of the ingredients. stop use and ask a doctor if irritation or redness develops and continues for more than 72 hours.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

d&a usa, llc - ethyl alcohol 15%. purpose: antiseptic, benzalkonium chloride 0.1%. purpose: antiseptic - antiseptic on children less than three years old and on skin wounds. irritation or rash appears and lasts. - for hand washing to decrease bacteria on the skin. - apply topically to the skin to help prevent cross contamination.

מלטה - אנגלית - Medicines Authority

xantis pharma limited lemesou, 5 eurosure tower, 1st floor, flat/office 101, 2112, nicosia, cyprus - azelastine hydrochloride - nasal spray, solution - azelastine hydrochloride 0.14 mg - nasal preparations

ארצות הברית - אנגלית - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - major depressive disorder paroxetine tablets, usp are indicated for the treatment of major depressive disorder. the efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine in hospitalized depressed patients have not been adequately studied